09/16/2026

Recent Oncology Related FDA Approvals and Expanded Indications

 

FDA Approves Jazz Pharmaceutical's Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus chemotherapy in first-line HER2+ Advanced Gastroesophageal Adenocarcinoma

 

FDA approves Takeda's MIMRYLO™ (rusfertide), a treatment for adults with Polycythemia Vera

More Info